IDO1 and metastatic melanoma: The phase III ECHO‐301/Keynote 252 trial of Epacadostat plus pembrolizumab versus pembrolizumab alone in patients with unresectable or metastatic melanoma showed no significant benefit with IDO1 inhibition.62